ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer ...Middle East

Efficacy signals observed will not achieve ESSA's target product profile in patients with metastatic castration-resistant prostate cancer naïve to second-generation antiandrogens A futility analysis conducted as part of a protocol-specified interim review of the safety, PK and efficacy...

Hence then, the article about essa pharma announces termination of phase 2 study evaluating masofaniten combined with enzalutamide in patients with metastatic castration resistant prostate cancer was published today ( Friday 01/11/2024 - 04:00 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( ESSA Pharma Announces Termination of Phase 2 Study Evaluating Masofaniten Combined with Enzalutamide in Patients with Metastatic Castration-Resistant Prostate Cancer )

Also on site :

• For Iran’s Rulers, Refusing U.S. Demands Is a Risk Worth Taking
• Masonite International Corporation Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - DOOR
• Battered by Gaza war, Israel's tech sector in recovery mode